Pulmonary diffusion capacity in patients with systemic lupus erythematosus

Area of Science:

• Rheumatology
• Pulmonology
• Immunology

Background:

• Systemic lupus erythematosus (SLE) can affect multiple organs, including the lungs.
• Pulmonary function tests (PFTs) are crucial for assessing respiratory involvement in SLE.
• Carbon monoxide diffusion capacity (DLCO) is a key PFT parameter reflecting gas exchange efficiency.

Purpose of the Study:

• To characterize PFT findings, particularly DLCO, in SLE patients.
• To investigate the correlation between DLCO and clinical/immunological features in SLE.
• To evaluate the impact of corticosteroid therapy on DLCO in SLE.

Main Methods:

• Retrospective analysis of PFTs (VC, DLCO) in 110 Japanese SLE patients.
• Serial PFT measurements during high-dose corticosteroid therapy in 38 patients.
• Correlation analysis with clinical (Raynaud's phenomenon) and immunological data (anti-RNP).

Main Results:

• Reduced DLCO observed in 47% of SLE patients, often without restrictive PFT patterns or pulmonary fibrosis.
• DLCO impairment correlated with Raynaud's phenomenon and the presence of anti-RNP antibodies.
• No significant change in DLCO was observed after corticosteroid therapy, despite immunological improvement.

Conclusions:

• DLCO impairment is common in SLE patients, even those without overt respiratory issues.
• Clinical (Raynaud's phenomenon) and immunological (anti-RNP) factors are associated with DLCO reduction in SLE.
• DLCO levels did not correlate with overall SLE disease activity and were not significantly altered by corticosteroid treatment.